Novo Nordisk's pricing tactics while in the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who may have accused the company of rate gouging, pointing out the stark distinction among U.S. price ranges and those in Europe and copyright. Rybelsus and copyright prompted